Bioniche & University of Ottawa Sign Exclusive License for Natural Health Technology to reduce anxiety / l’Université d’Ottawa signent un accord de licence pour la technologie avec potentielles pour réduire l’anxiété

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, together with the University of Ottawa, one of Canada’s top ten research universities, today announced the signing of an exclusive global license agreement. The agreement provides commercial access for Bioniche to University of Ottawa’s technology for botanical therapeutics (natural health) and pharmaceutical compounds for treating anxiety and related conditions in animal health, human health and aquaculture. Read more of this post

Jennerex Completes Private Placement

San Francisco, California, August 19, 2010 – Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer, today announced the closing of a fully subscribed private placement financing with aggregate gross proceeds of approximately $8.6 million. Proceeds from this transaction will be used to advance the Company’s oncology product platform, led by JX-594, a novel oncolytic agent that has demonstrated promising antitumor activity in Phase 1 and Phase 2 clinical trials. Read more of this post